{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":null,"name":"NCT04429087","nct_id":"NCT04429087","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct04429087. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":null,"label":"Arm 1: Obrixtamig","type":"EXPERIMENTAL"},{"description":null,"label":"Arm 2: Obrixtamig","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2027-10-01","type":"ESTIMATED"},"conditions":["Small Cell Lung Carcinoma and Other Neuroendocrine Neoplasms Expressing DLL3"],"enrollment":{"count":306,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Obrixtamig - parenteral 1","otherNames":["BI 764532"],"type":"DRUG"},{"name":"Obrixtamig - parenteral 2","otherNames":["BI 764532"],"type":"DRUG"}],"last_update":"2026-09-21","lead_sponsor":"Boehringer Ingelheim","official_title":"A First-In-human Phase I, Non-randomized, Open-label, Multi-center Dose Escalation Trial of Obrixtamig (BI 764532) Administered by Parenteral Route in Patients With Small Cell Lung Carcinoma and Other Neuroendocrine Neoplasms Expressing DLL3","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1"],"primary_completion_date":{"date":"2026-08-31","type":"ACTUAL"},"primary_outcomes":[{"measure":"Arm 1 and Arm 2: Maximum tolerated dose (MTD)","timeFrame":"up to 36 months"},{"measure":"Arm 1 and Arm 2: Number of patients with DLTs in the MTD evaluation period","timeFrame":"up to 36 months"}],"references":[{"citation":"Wermke M, Felip E, Gambardella V, Kuboki Y, Morgensztern D, Hamed ZO, Liu M, Studeny M, Owonikoko TK. Phase I trial of the DLL3/CD3 bispecific T-cell engager BI 764532 in DLL3-positive small-cell lung cancer and neuroendocrine carcinomas. Future Oncol. 2022 Aug;18(24):2639-2649. doi: 10.2217/fon-2022-0196. Epub 2022 Jul 11.","pmid":"35815644","type":"DERIVED"}],"start_date":{"date":"2020-07-29","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study to Test Different Doses of Obrixtamig in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3","url":"https://clinicaltrials.gov/study/NCT04429087"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct04429087"}